Plain-English translation of NCT06012552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help treat 'brain fog'—the memory, attention, and thinking problems that some people experience after recovering from COVID-19. You would take the medication (or a placebo) for 16 weeks, along with group therapy and rehabilitation exercises designed to help your brain heal and your thinking improve.
Many people who recover from COVID-19 struggle with brain fog and cognitive difficulties that seriously affect their daily lives, but there are currently no proven treatments for it. Researchers believe this medication may help protect the brain and reduce these symptoms, and they want to test whether it works.
You likely qualify if…
You likely don't qualify if…
Over 16 weeks, you would take a daily pill (either the medication or a placebo—you won't know which) along with group psychotherapy sessions and neurological rehabilitation exercises designed to help your brain recover. You would also undergo special brain scans and other tests at the beginning and end of the study to measure changes in your thinking and brain function. The study involves regular visits to the research center and commitment to the weekly therapy and rehabilitation program.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Poland